US 9339497

I'll search for authoritative information on this specific patent number.

Let me look specifically for the patent's claims and any 2026 litigation activity.

Now let me check the litigation dockets and verify the claim text from an independent source.

US Patent 9,339,497 — Summary

Note on sources: The authoritative full text you provided was truncated at the end of the Detailed Description (before the "Claims" section). Claim text below is therefore taken from a secondary aggregator (DrugPatentWatch's claim listing), which is consistent with the Orange Book use code for this patent. I flag the one independent claim whose text was cut off in that source.

---

Bibliographic data

Earlier priority date listed by Google Patents (prior-art date): 2012-06-13.

Abstract (verbatim)

"Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin."

Orange Book / commercial relevance

• The patent is listed for ONIVYDE (irinotecan hydrochloride, liposomal, IV), NDA 207793-001, approved Oct. 22, 2015 (applicant of record at approval: Merrimack; now Ipsen).
• Listed use code: U-1848 — "Treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin."
• Listed patent expiration: 2033-06-12.

---

Plain-language overview of the independent claims

Claim 1 (independent): A method of treating metastatic adenocarcinoma of the pancreas in a human patient who has previously been treated with gemcitabine, by intravenously giving, once every two weeks, 80 mg/m² of MM-398 liposomal irinotecan together with either 200 mg/m² (l)-leucovorin or 400 mg/m² (l+d)-racemic leucovorin and 2,400 mg/m² 5-FU — with the negative limitation that no other antineoplastic agent is administered for that pancreatic cancer.

In other words: the classic second-line regimen of nanoliposomal irinotecan (Onivyde) + 5-FU/LV on a 2-week cycle, at those specific doses, in gemcitabine-pretreated metastatic pancreatic adenocarcinoma patients, as monotherapy regimen (no additional antineoplastic agent).

Claim 12 (independent): A second independent method claim directed to treating metastatic adenocarcinoma of the pancreas in a gemcitabine-pretreated patient, comprising intravenously administering once in a 2-week cycle, beginning on day 1 … — the text of this claim was truncated in the source I could access; I cannot state its full scope with confidence.

Representative dependent claims (2–11): add specifics such as — leucovorin as the 400 mg/m² (l+d) racemic form (cl. 2); administration spread over 48 hours (cl. 3); leucovorin before 5-FU (cl. 4); MM-398 before leucovorin (cl. 5); pre-medication with dexamethasone plus a 5-HT3 antagonist/anti-emetic (cl. 6); patient's cancer having progressed on gemcitabine-based therapy (cl. 7); MM-398 infused over 90 minutes (cl. 8); leucovorin over 30 minutes and 5-FU over 46 hours (cl. 9); the specific sequence MM-398 (90 min) → leucovorin (30 min) → 5-FU (46 h) (cl. 10); repeated 2-week cycles beginning day 1 with 400 mg/m² racemic leucovorin (cl. 11).

⚠️ Important caveat: The specification's Summary section describes a broader genus than the granted claims — e.g., a 3-week cycle at 120 mg/m² (80 mg/m² for UGT1A128 homozygotes), 2-week cycles with a 60 mg/m² starting dose for UGT1A128 homozygotes, kits, and a "method of improving chemotherapy outcomes by increasing tumor vascularity." Based on the sources retrieved, the granted independent claims are directed to the 80 mg/m² q2w second-line regimen, not to those broader embodiments (which appear to be pursued in related family members such as US 9,364,473; 9,452,162; 9,492,442; 9,717,724; 10,980,795; 11,369,597). I would want to verify the exact granted claim set directly from the issued patent to be certain.

---

Litigation / docket status (searched)

• District Court (D.N.J.): Ipsen Biopharmaceuticals, Inc. et al. v. Conjupro Biotherapeutics, Inc., CSPC Pharmaceutical Group Ltd., CSPC Ouyi Pharmaceutical Co., Ltd., Civil Action No. 3:24-cv-04991 (RMB)(MJS), filed April 15, 2024, before Judge Renee Marie Bumb. U.S. Patent 9,339,497 (the "'497 patent") is expressly among the patents-in-suit, alongside 8,329,213; 9,364,473; 9,452,162; 9,492,442; 9,717,724; 10,980,795; and 11,369,597. The action arises from Conjupro's Paragraph IV certification on its proposed irinotecan liposome injection (NDA 218923). It was later consolidated with No. 24-8723 (Aug. 23, 2024, re U.S. 12,059,497) and No. 25-13647 (July 22, 2025, re a "'691" patent).
• CAFC 2026 dockets: I found no Federal Circuit appeal in 2026 specifically involving U.S. Patent 9,339,497, and no CAFC docket matching this patent number. My search returned only unrelated 2026 Federal Circuit matters (e.g., Ablynx/Sanofi ODP appeals). I cannot confirm any appellate activity for this patent — treat this as "none found," not as a definitive negative.
• Google Patents also flags a "First worldwide family litigation filed" entry via Darts-IP (family 48692681).

---

Uncertainty statement

• The claim text above is drawn from a secondary patent-data aggregator, not directly from the issued patent document (the copy provided to me ended before the claims). Claim 1 and claims 2–11 appear reliable and consistent with the Orange Book use code; claim 12's full text and the total claim count could not be verified.
• Assignee history and litigation details are per Google Patents, FDA/Orange Book listings, PACER/aggregator dockets, and are correct as of the sources' last-updated dates; dockets evolve and should be re-checked on PACER/USPTO Patent Center for current status.
• "Affective amount" appears literally in the specification text (likely a typographical error for "effective amount"); I have not auto-corrected it.

I'll research litigation involving US patent 9339497 across patent litigation databases and court records.

Let me dig into the specific litigation referenced and search patent litigation databases.

I have good initial data. Let me verify and look for any additional cases involving this patent.

Litigation Involving U.S. Patent No. 9,339,497

Bottom line: Based on the searches performed, the only litigation I can identify that expressly asserts U.S. Patent No. 9,339,497 ("the '497 patent") is the Hatch‑Waxman (ANDA / 505(b)(2)) action brought by Ipsen against Conjupro Biotherapeutics / CSPC Ouyi in the District of New Jersey. I found no CAFC appeal, ITC action, or other case asserting the '497 patent specifically. I could not confirm a final judgment or settlement, so the matter appears to be pending.

---

Case 1 — Ipsen Biopharmaceuticals, Inc. v. Conjupro Biotherapeutics, Inc. (lead case)

The '497 patent in this case: It is one of the eight original patents‑in‑suit. The complaint summary describes the '497 patent as claiming "methods of treating pancreatic cancer with a combination therapy of liposomal irinotecan, 5-fluorouracil, and leucovorin, including claims directed to patients with specific genetic markers (UGT1A1*28 allele)." Its Orange Book expiration date is listed as 2033-06-12.

---

Consolidated / Related Actions in the Same Family of Suits

These are separate complaints that were consolidated into the lead case. The '497 patent was asserted only in the first (April 15, 2024) complaint:

1. Ipsen Biopharmaceuticals, Inc. v. Conjupro Biotherapeutics, Inc. — 1:24-cv-08723 (a.k.a. 24-8723 (RMB)(MJS)), filed August 23, 2024. Asserted a single newly issued patent, U.S. 12,059,497 ("Stabilizing Camptothecin Pharmaceutical Compositions"), not listed in the Orange Book at filing. Consolidated with 24-4991 on October 18, 2024.

2. Ipsen Biopharmaceuticals, Inc. v. Conjupro Biotherapeutics, Inc. — 1:25-cv-13647 (a.k.a. 25-13647 (RMB)(MJS)), filed July 22, 2025. Asserted U.S. 12,364,691, also not Orange‑Book listed at filing. Consolidated with 24-4991 on August 21, 2025.

---

Related USPTO Proceedings (Note — different patents)

These are relevant background but do not involve the '497 patent:

• IPR 25-00505 — Conjupro Biotherapeutics petition for inter partes review of U.S. 11,344,552. Instituted for trial; oral argument scheduled May 19, 2026 (per ParagraphFour).
• IPR 25-01531 — Apotex Inc. petition for inter partes review of U.S. 11,344,552. Joined to the Conjupro IPR and instituted for trial (per ParagraphFour).

---

Caveats on This Answer

• I did not locate any litigation asserting the '497 patent against any defendant other than Conjupro/CSPC.
• I found no CAFC appeal and no PTAB proceeding directed at the '497 patent itself.
• Case dockets are dynamic; the "pending" characterization reflects the latest data returned in search (DrugPatentWatch dated Aug. 3, 2026; ParagraphFour entries through ~Sept. 2025) and may not capture very recent orders, settlements, or stipulations.
• The case number appears in the sources in both "1:24-cv-04991" and "3:24-cv-04991" forms (the Google Patents panel uses the Unified Patents designation 3:24-cv-04991; the complaint/counterclaim and DrugPatentWatch use 1:24-cv-04991 / 24-4991). Both refer to the same New Jersey action.

Sources

• Google Patents — US9339497B2 (litigation panel, case 3:24-cv-04991): https://patents.google.com/patent/[US9339497](/patent/US9339497)/en
• ParagraphFour (Paragraph IV activity entry for Onivyde®/Conjupro): https://paragraphfour.com/members/parryashford/activity/11735/
• DrugPatentWatch litigation summary for Ipsen Biopharmaceuticals, Inc. v. Conjupro Biotherapeutics, Inc. (1:24-cv-04991)
• D.N.J. counterclaim record (C.A. No. 24-4991, 24-8723, 25-13647 consolidation history): https://paragraphfour.com/wp-content/uploads/2024/04/njdc25cv13647A.pdf
• USPTO PTAB petition documents referencing the '497 patent and related family: https://ptacts.uspto.gov/ptacts/public-informations/petitions/[1557313](/patent/1557313)/download-documents
• Ex Parte complaint analyses for 1:24-cv-04991 and 1:24-cv-08723

Would you like me to attempt to pull the more recent docket entries or check for any settlement/stipulation of dismissal?

I'll start by checking the structured data block and then verify against live sources.

The structured "PTAB proceedings on file" block states: no AIA trial proceedings on file for US 9,339,497 as of the most recent ODP ingest. Let me probe for anything ODP may not have indexed.

No hits yet. Let me probe more targeted angles — the litigation chain, the patent owner, and the drug product.

Let me check whether the sibling-patent IPRs also targeted the '497 patent, and look directly at PTAB E2E / docket aggregators.

PTAB / AIA Trial Landscape — US 9,339,497 B2

Patent: US 9,339,497 B2 — Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
Assignee: Ipsen Biopharm Ltd. (originally Merrimack Pharmaceuticals, Inc.)
Priority: 2012-06-13 · Filed: 2015-07-29 · Granted: 2016-05-17 · Anticipated expiry: 2033-06-12
Source of record for proceedings: structured "PTAB proceedings on file" block (USPTO Open Data Portal) supplied with this task.

---

Proceedings overview

Total AIA trial proceedings on file against US 9,339,497: 0. Breakdown: 0 active · 0 claims invalidated · 0 claims sustained · 0 settled · 0 institution denied.

Bottom line for a defendant: the patent has never been through an IPR, PGR, or CBM trial. Every claim is UNCHALLENGED and UNTESTED at the PTAB, the full claim set is intact, and no § 315(e)(2) estoppel exists against anyone. Unlike the "claims 1–5 have been canceled" posture, here the patent is at full strength procedurally — there is no PTAB record to lean on, and any invalidity defense you intend to run must be built from scratch (in the IPR you file, or in district court).

Because the canonical list is empty, no per-proceeding entries can be generated. A "for each proceeding" section would be fabricated, so I have not written one. Instead, below is a clearly-labeled account of adjacent family activity that is not a proceeding on this patent — useful as a pattern signal, and easy to misread as an IPR on the '497.

---

Adjacent family activity (NOT proceedings against US 9,339,497)

These challenge sibling/continuation patents in the same Ipsen family — not the '497. I flag them for pattern purposes only.

• IPR2025-01531 — Apotex, Inc. v. Ipsen Biopharm Ltd., U.S. Patent No. 11,344,552
  • Patent Owner's Preliminary Response at https://paragraphfour.com/wp-content/uploads/2024/04/ipr25-1531PR.pdf
  • The '552 patent is directed to the first-line "NALIRIFOX" regimen (liposomal irinotecan + oxaliplatin + 5-FU/LV). Ipsen states the '552 claims have an effective filing date of 2015-08-21 — a different priority family from the '497 (2012-06-13).
  • Grounds as characterized by Ipsen: obviousness over Conroy (FOLFIRINOX) and Bayever, plus Masi/Ginocchi and Carnevale/Dean theories. Ipsen's response leans heavily on § 325(d) (same art considered during prosecution) and hindsight.
• CSPC Pharmaceutical Group Ltd. / CSPC Ouyi / Conjupro Biotherapeutics v. Ipsen Biopharm Ltd., U.S. Patent No. 11,344,552
  • Ipsen's Request for Discretionary Denial (PTAB P-TACTS petition 1557313) invokes the Director's 2025-03-26 workload-management memo, § 325(d), and "settled expectations." Companion filings (petition 1558479) likewise reference the '552 patent's Conroy/Bayever overlap.
• Pattern note: the same accused infringer group (CSPC / Conjupro) is the defendant in the parallel Hatch-Waxman action, and the same lead references (Conroy, Bayever) recur across petitions.

Why this matters but is not dispositive: these petitions show that Ipsen's newer Onivyde-family patents are under active PTAB attack and that Ipsen defends them hard. They say nothing about the validity of the '497, and they create no estoppel as to the '497.

---

Underlying district-court context (for a defendant)

• Ipsen Biopharma Inc. v. Conjupro Biotherapeutics, Inc. et al., D.N.J. — Google Patents' litigation record lists this as 3:24-cv-04991 (https://portal.unifiedpatents.com/litigation/New%20Jersey%20District%20Court/case/3%3A24-cv-04991); a secondary source renders it 1:24-cv-04991. I could not definitively reconcile the two case numbers; treat the D.N.J. docket number as unverified.
• The action arises from NDA No. 218923 (Conjupro/CSPC irinotecan liposome injection) against branded Onivyde® (NDA No. 207793).
• US 9,339,497 is one of the asserted patents-in-suit, alongside US 8,329,213; US 9,717,724; US 10,980,795; and US 11,369,597 (per the complaint analysis at https://ai-lab.exparte.com/case/dct/njd/1:24-cv-04991/doc/analysis/1). The '497 is listed in the Orange Book for Onivyde under use code U-1848 (second-line/after-gemcitabine indication).
• Google Patents also flags a "First worldwide family litigation" entry via Darts-IP (family 48692681) — a signal that the family is being enforced in multiple jurisdictions, not evidence of PTAB activity.

---

Strategic summary

Claim status — all UNTESTED. No claim of the '497 has been canceled, confirmed, or even construed by the PTAB. Nothing has been narrowed administratively. (For completeness: the specification/summary describes a 3-week-cycle monotherapy method at 120 mg/m² — 80 mg/m² for UGT1A1*28 homozygotes — a 2-week combination method with 5-FU/LV, kit and formulation aspects, and a tumor-vascularity method. I am describing disclosed aspects; I have not verified the issued claim numbers from the face of the patent, and no PTAB paper assigns claim numbers here.)

Estoppel landscape — wide open. § 315(e)(2) estoppel attaches only after a final written decision. With no IPR/PGR on this patent, no petitioner is estopped from anything, and conversely you are not bound by any prior panel's claim constructions or invalidity findings. Every prior-art ground — §§ 102/103/112 — is available to you, subject only to § 315(b)'s one-year bar running from service of a complaint alleging infringement of the '497, and to the discretionary-denial framework now in force (the Director-level institution process and the proposed rules on parallel challenges described in the 2025-10-16 Squires memo, https://www.willkie.com/publications/2025/10/ptab-announces-new-institution-policy). Given that the challenged patent is more than ten years old and the parallel D.N.J. case is mature, expect § 325(d)-style and Fintiv/"settled expectations" discretionary-denial pressure — the same playbook Ipsen is running on the '552.

Pattern signals. (1) No serial petitioner on the '497, because there have been zero petitions. (2) The same challenger group (CSPC/Conjupro/Apotex) is attacking the family's newer members instead. (3) No defensive aggregator (e.g., Unified Patents) appears in the chain on the '497 — the only Unified-related link is the open litigation-data portal, not a filed IPR. (4) Ipsen is an aggressive patent owner at the PTAB: it files full preliminary responses, invokes § 325(d), and litigates discretionary denial — so if you do petition, expect a hard fight.

---

Recommended next steps

1. No PTAB record exists on the '497 — do not cite one. There is no FWD to link, no canceled claims to quote, and no estoppel to inherit. Any demand-letter response that assumes the '497 has been invalidated at the Board is factually wrong.
2. Verify currency before relying on the "zero" figure. The ODP block is canonical, but it is an ingest snapshot. Confirm in PTAB E2E / P-TACTS (https://ptacts.uspto.gov) under "Patent No. 9,339,497" and cross-check the USPTO Patent Center "PTAB" tab at https://patentcenter.uspto.gov. (I hit my search-step limit before I could exhaustively poll current 2025–2026 filings; the structured data is the default and it says none.)
3. If you intend to file a petition: calculate your § 315(b) one-year deadline from service of the D.N.J. complaint asserting the '497 (filed 2024), and budget for the parallel-litigation discretionary-denial fight. Institution, if granted, is followed by a statutory 1-year trial deadline from the institution date (35 U.S.C. § 316(a)(11)).
4. Copy Ipsen's family-wide playbook at your peril — but study it: the '552/Apotex and '552/CSPC papers show exactly which references Ipsen treats as its dangerous art (Conroy/FOLFIRINOX, Bayever) and which § 325(d) posture it will run against you.
5. Belt-and-suspenders: if you are the accused infringer in the Onivyde-android space, a validity attack aimed at the '497 must be paired with attacks on the newer family members ('552, '597, '724, '10,980,795) — the IPR battleground to date is on those, not on the '497.

---

Citations & provenance

• Canonical proceedings list: structured "PTAB proceedings on file" block (USPTO ODP) — empty for US 9,339,497.
• Patent bibliographic data: https://patents.google.com/patent/US9339497/en
• Sibling-patent IPRs (not this patent): IPR2025-01531 POPR — https://paragraphfour.com/wp-content/uploads/2024/04/ipr25-1531PR.pdf; Ipsen discretionary-denial request re the '552 patent (P-TACTS petition 1557313) — https://ptacts.uspto.gov/ptacts/public-informations/petitions/1557313/download-documents
• Litigation reference: https://portal.unifiedpatents.com/litigation/New%20Jersey%20District%20Court/case/3%3A24-cv-04991; complaint analysis at https://ai-lab.exparte.com/case/dct/njd/1:24-cv-04991/doc/analysis/1
• PTAB policy context (2025): https://www.willkie.com/publications/2025/10/ptab-announces-new-institution-policy

Confidence note: High confidence that no AIA trial proceeding has issued a decision on the '497 (no institution decisions, FWDs, or CAFC appeals surfaced). Medium confidence that none has ever been filed, because I could not fully poll the most recent 2025–2026 petition filings beyond the ODP snapshot before exhausting search steps. Any proceeding found on further verification would be a new filing, not a decided case.

I'll work from the authoritative patent text provided and cross-check the assignment and litigation records with live sources. Let me run several searches.

Let me try to pin down the actual USPTO assignment records (reel/frame and correspondent).

Ownership & Assignment Record — US 9,339,497 B2

Sources actually used (and their limits): The authoritative full text you supplied carries the Google Patents legal events block, which is the only structured assignment data I could confirm for this patent. I then cross-checked against SEC filings (Merrimack 8-K of 2017-01-09 and 2017-04-05, 10-K/10-Q series), the Ipsen press release of 2017-04-03, and the D.N.J. docket / Paragraph Four tracker for the 2024–25 litigation.

Two fields could not be retrieved and are NOT fabricated below:

• Reel/Frame numbers — the Google Patents legal-events block does not expose them, and my queries against the Assignment Center / assignment.uspto.gov did not return indexed reel-frame data for this record. They must be read directly off the Assignment Center UI.
• Correspondent of record (attorney/firm) — likewise not exposed by any source I could reach. This is the single most diagnostic field for the question you asked and it remains unverified.

Every date below is reproduced as the legal-event date shown by Google Patents (which is generally the recordation/effective date); treat the "executed" vs. "recorded" split as to be confirmed at the Assignment Center.

---

Inventors

Seven named inventors (all listed on the face of US 9,339,497 B2):

Pattern note: All seven are Merrimack employees; this is a pure corporate-employee invention set, not an acquired-in inventor group. The one mild anomaly is Jaeyeon Kim, whose inventor assignment was not recorded with the original six (2015-11-23); it was recorded separately on 2016-03-31, i.e. after the patent's 2016-05-17 grant and ~3.5 years after the 2012-06-13 priority date. A late inventor assignment capture is an administrative cleanup, not a fire-sale tell.

The more relevant departure signal is tied to the asset sale, not to the patent: Merrimack's 8-K of 2017-01-09 disclosed that Peter Laivins, William McClements, Edward Stewart and William Sullivan would all leave effective the later of asset-sale closing and 2017-03-10, and that Ipsen agreed to make offers of employment to certain identified Merrimack employees as of closing. So the ONIVYDE team (inventors included) largely moved with the asset to Ipsen. That is the opposite of the "inventors all bail, patent gets dumped" precursor — the buyers wanted the people.

---

Original assignee

Merrimack Pharmaceuticals, Inc., One Kendall Square, Cambridge, MA (Nasdaq: MACK).

• Product shipped embodying the claims: yes. ONIVYDE® (irinotecan liposome injection, MM-398) received FDA approval in October 2015 for metastatic adenocarcinoma of the pancreas after gemcitabine failure; Merrimack recorded $53.1M of ONIVYDE product revenue for FY2016 (per its 2017-03-01 results release). The patent is listed in the Orange Book against NDA 207793.
• Primary line of business: clinical-stage oncology / nanoliposomal drug delivery, with this one commercial product.
• Current status: operating but divested of this asset. On 2017-01-07 Merrimack signed an Asset Purchase and Sale Agreement with Ipsen S.A.; the sale closed 2017-04-03 for $575M upfront (reported elsewhere as $580.7M after a working-capital adjustment), plus up to $450M in FDA-approval milestones. Merrimack was not in bankruptcy — it was an announced, board-approved, stockholder-conditioned sale that was contested only by convertible-noteholders in Delaware Chancery (Wells Fargo v. Merrimack). After the sale, Merrimack retained non-commercial pipeline assets (MM-121, MM-141, MM-310) and now has no products approved for sale. Note the 2020-03-27 8-K: Merrimack sold its remaining preclinical nanoliposome programs to Celator and assigned to Celator its 2017 Ipsen IP license — i.e. Merrimack retained a license-back rather than the patents themselves.

---

Assignment timeline

Pre-assignment context (not an assignment): 2015-07-29 — continuation application US 14/812,950 filed by Merrimack (parent: Ser. No. 14/406,776, the §371 national phase of PCT/US2013/045495, filed 2013-06-12; priority 2012-06-13). Issued 2016-05-17 as US 9,339,497 B2.

1. 2015-11-23 (recorded/effective; executed date TBC) — Reel/frame: not retrieved

• Conveyance: Assignment of Assignors' Interest (inventor → company)
• Assignor: Clet Niyikiza; Victor Moyo; Eliel Bayever; Jonathan Basil Fitzgerald; Navreet Dhindsa; Peter Laivins
• Assignee: Merrimack Pharmaceuticals, Inc.
• Correspondent: not retrieved — flag: this is the first link that should have been filed by Merrimack's outside IP counsel; verify whether the same firm recurs on link 6.
• Context: routine employee invention assignment perfecting company title.

2. 2015-12-28 — Reel/frame: not retrieved

• Conveyance: Security Interest / Security Agreement
• Assignor: Merrimack Pharmaceuticals, Inc.
• Assignee: U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT
• Correspondent: not retrieved
• Context: securitization — collateral lien supporting Merrimack's 11.5% senior secured notes due 2022, which were secured by "substantially all of Merrimack's assets." Not a title transfer.

3. 2016-03-31 — Reel/frame: not retrieved

• Conveyance: Assignment of Assignors' Interest
• Assignor: Kim, Jaeyeon
• Assignee: Merrimack Pharmaceuticals, Inc.
• Correspondent: not retrieved — flag: if this shares a correspondent with link 1, that is normal inside-counsel consistency, not an NPE tell.
• Context: late-filed inventor assignment (administrative correction).

4. 2017-04-14 — Reel/frame: not retrieved

• Conveyance: Release by Secured Party
• Assignor: U.S. Bank National Association (collateral agent)
• Assignee: Merrimack Pharmaceuticals, Inc.
• Correspondent: not retrieved
• Context: lien release — the secured notes were redeemed out of the Ipsen sale proceeds; the encumbrance on this patent was cleared to permit clean transfer.

5. 2017-05-01 — Reel/frame: not retrieved

• Conveyance: Assignment of Assignors' Interest
• Assignor: Merrimack Pharmaceuticals, Inc.
• Assignee: IPSEN BIOPHARM LTD. (Ash Road, Wrexham Industrial Estate, Wrexham LL13 9UF, United Kingdom)
• Correspondent: not retrieved — flag: this is the link where the correspondent matters most for your question; on the pharma-asset-sale side these are almost always filed by an outside M&A/IP firm, and a single firm here is expected and benign. Do not treat a repeat name here as an NPE signal without a second, independent datum (e.g. an operating-company roster overlap).
• Context: acquisition — part of the disclosed $575M+ ONIVYDE/MM-436 Commercial Business asset sale to Ipsen (signed 2017-01-07, closed 2017-04-03); accompanied by a cross-license-back to Merrimack.

6. 2017-05-17 — Reel/frame: not retrieved

• Conveyance: Change of Address of Assignee
• Assignor: Merrimack Pharmaceuticals, Inc. (as parsed by Google Patents — almost certainly a data-quirk in the source attribution; a change-of-address record is normally filed by/for the assignee, Ipsen)
• Assignee: Ipsen Biopharm Ltd.
• Correspondent: not retrieved
• Context: change of name/address only — purely administrative, no change in substantive ownership.

No assignment records beyond 2017-05-17 are surfaced for this patent. I could not independently confirm from the Assignment Center that the list above is exhaustive — treat exhaustiveness as unverified.

---

Timeline diagram

timeline
    title Ownership of US 9339497
    2012 : Priority date
    2013 : PCT application filed
    2015 : Continuation US 14 812 950 filed
         : Inventors assign to Merrimack
         : US Bank security interest recorded
    2016 : Jaeyeon Kim assignment recorded
         : Patent issues as US 9339497
    2017 : Security interest released
         : Asset sale to Ipsen Biopharm Ltd
         : Assignee address change recorded
    2024 : Ipsen files infringement suit

---

NPE / troll-pattern signals

1. Shell-entity transfer — NOT PRESENT. The only operating-company-to-licensee transfer is link 5, Merrimack → Ipsen Biopharm Ltd (2017-05-01). Ipsen Biopharm Ltd is an operating pharmaceutical manufacturer (Ash Road, Wrexham, UK), not a Delaware/Texas single-member LLC, and its affiliate Ipsen Biopharmaceuticals, Inc. markets ONIVYDE in the U.S. No "IP/Holdings/Licensing/Ventures" transferee appears at any link.

2. Known asserter in the chain — NOT PRESENT. Neither Merrimack nor Ipsen appears on the enumerated lists (Acacia, Marathon, IV, IPNav, Wi-LAN, Mosaid/Conversant, Vringo, Pendrell, Innovatio, MPHJ, Lumen View, Round Rock, Document Generation, Spangenberg). No Unified Patents / RPX high-frequency-plaintiff entity appears in the chain.

3. Repeat correspondent across the chain — UNVERIFIED / CANNOT BE ASSESSED. No correspondent data was retrievable for any of the six links. This is an explicit gap, not a negative finding. The signal requires recurrence across reel/frame entries; I have zero correspondent entries to compare. If you run this in the Assignment Center, the key comparison is link 1 / link 3 (Merrimack prosecution-side filings) vs. link 5 / link 6 (Ipsen-side filings) — and then whether that name recurs across other Ipsen-family patents, which would indicate ordinary portfolio-level outside counsel rather than an NPE filing mill.

4. Cascading transfers — NOT PRESENT. Seven events over ~20 months (2015-11 → 2017-05) looks like churn, but the substantive transfers are only two (inventor→Merrimack, Merrimack→Ipsen). The remainder are one securitization (link 2), its release (link 4), one late inventor assignment (link 3), and one address change (link 6). This is a normal encumber-then-divest pattern in an M&A context, not LLC-to-LLC cascading.

5. Pre-litigation transfer — NOT PRESENT. The operative transfer is 2017-05-01; the first suit naming this patent was filed 2024-04-15 (Ipsen Biopharmaceuticals, Inc. et al v. Conjupro Biotherapeutics, Inc. et al, D.N.J. 1:24-cv-04991; Google Patents lists it as 3:24-cv-04991). The gap is ~7 years — the assignment was plainly not arranged to enable that suit.

6. Bankruptcy fire-sale — NOT PRESENT (with nuance). Merrimack never filed Chapter 7/11. The 2017 transfer was a negotiated $575M asset sale requiring stockholder approval, with employment offers to Merrimack staff and a $450M contingent milestone tail retained by the seller. The only adversarial element — Wells Fargo Bank, N.A., et al. v. Merrimack Pharmaceuticals, Inc. (Del. Ch.) over the convertible notes — sought to block a special dividend; it did not produce a distressed patent sale.

7. Privateering — NOT PRESENT. Ipsen did not take the patent to a third-party NPE to assert on its behalf. Ipsen is itself the plaintiff of record (with Ipsen Biopharmaceuticals, Inc.), enforcing a product it manufactures and sells, against generic/505(b)(2) entrants. A cross-license-back was retained by Merrimack for its other pipeline fields — that is a field-of-use carve-out on disposition, not privateering.

8. Defensive aggregator — NOT PRESENT. The chain terminates at Ipsen Biopharm Ltd, an operating pharma. No RPX / AST / LOT / Unified / OIN.

Additional litigation context (from the Paragraph Four tracker and the D.N.J. counterclaim filings): the 2024-04-15 complaint asserted eight patents including the '497 patent; Ipsen filed second (24-8723, 2024-08-23) and third (25-13647, 2025-07-22) actions, consolidated into 24-4991. Conjupro filed IPR 25-00505 (instituted, oral argument 2026-05-19) and Apotex filed IPR 25-01531, joined. Plaintiffs' counsel of record in the D.N.J. actions is Sterlington LLP (Brian V. Slater / Gregory B. Sephton / Charles M. Baton, One World Trade Center, 85th Floor, New York). To be clear: that is litigation counsel, not the assignment-record correspondent — I am listing it only so you don't conflate the two when you pull the reel/frame records.

---

Verdict

Operating-company assertion.

Ipsen Biopharm Ltd acquired this patent as part of a $575M+ negotiated purchase of Merrimack's ONIVYDE commercial business (Merrimack → Ipsen Biopharm Ltd, link 5, 2017-05-01, preceded by the 2017-04-14 release of U.S. Bank's security interest recorded 2015-12-28), and it is the Orange Book-listed patent covering a product Ipsen actually manufactures and sells. Ipsen is now asserting it directly against real generic competitors — Conjupro/CSPC and, via IPR, Apotex — under 35 U.S.C. § 271 in D.N.J. 1:24-cv-04991. Not one of the eight enumerated NPE signals is present on the evidence available; signals 3 (repeat correspondent) is unverified purely because the Assignment Center's reel/frame and correspondent fields were not retrievable in this session, which is a data gap rather than a finding.

Verification link: https://assignmentcenter.uspto.gov/ (or https://assignment.uspto.gov/patent/index.html — search by patent number 9339497). When you pull it, the two things worth recording are (a) the executed vs. recorded dates for links 1 and 5, and (b) the correspondent on each of the six reel/frame entries, to close out signal 3.

I'll research US Patent 9,339,497 and its cited prior art. Let me run several targeted searches.

Let me pull the specific citation lists (both cited patent documents and cited non-patent literature).

I have a partial citation list. Let me retrieve the complete "Patent Citations" and non-patent literature sections.

Prior-Art Analysis — US Patent 9,339,497 B2

Note on method and limits. I searched for the specific number 9,339,497 (rendered literally as US 9,339,497 B2 / US9339497B2; application 14/812,950). I was able to confirm the identity of the patent and recover its US patent-document citation list. I could not fully recover the patent's "Foreign Patent Documents" annex or its complete non‑patent‑literature list within this session's tool budget, so those portions below are flagged as incomplete rather than presented as complete. All dates/identifiers are transcribed as they appear in the sources; I did not auto‑correct anything.

1. The patent at issue (as confirmed)

Because the effective filing/priority date is 12 June 2012, §102 art must predate that date (pre‑AIA §102 applies, since the PCT was filed before 16 March 2013). Several cited documents were granted/published after 2012 only qualify, if at all, as §102(e)/§102(a)(2) art because they were "effectively filed" earlier (notably the Hong "Liposomes useful for drug delivery" family, whose priority traces to a much earlier application).

The claims (as granted, corresponding to the published application US 2015/0328156 A1) center on:

• Claim 1 – treating metastatic adenocarcinoma of the pancreas in a patient previously treated with gemcitabine by IV 80 mg/m² MM‑398 liposomal irinotecan + (l)-leucovorin 200 mg/m² or (l+d) leucovorin 400 mg/m² + 2,400 mg/m² 5‑FU.
• Claims 2–11 – dependents (racemic leucovorin; 2‑week cycles; sequence LV→5‑FU and MM‑398→LV; dexamethasone/5‑HT3 pre‑medication; progression on gemcitabine; 90‑min infusion; 30‑min LV / 46‑h 5‑FU).
• Claims 12–16 – parallel independent claims to the same 2‑week‑cycle, sequential‑administration regimen.

2. Cited US patent documents (the reference list)

All of the following are cited on the face of / in the prosecution of the '497 family (source: FreePatentsOnline record for 9339497). Dates in the "grant/pub" column are the dates given in the citation list.

(The FPO citation list also includes additional "US Patent References" entries beyond those reproduced here; the visible list was truncated at reference #26. I am reporting only what I could actually read rather than inventing entries.)

3. Non‑patent literature (family citations — flagged as not independently verified as the '497's own list)

The '497 family's related members (e.g., US 10,980,795; US 11,344,552; US 11,369,597) cite NPL that is highly pertinent to novelty of the claims and pre‑dates the priority date, including:

• Ko A, et al., "A multinational Phase II study of PEP02 (liposome irinotecan) for patients with gemcitabine‑refractory metastatic pancreatic cancer," J Clin Oncol. 29 (suppl; abstr 4069), 2011 ASCO Annual Meeting, Chicago, Jun. 3–7, 2011 — discloses liposomal irinotecan (PEP02/MM‑398) in gemcitabine‑refractory metastatic pancreatic cancer (monotherapy). This is the single most on‑point piece of art against the indication + drug elements of claim 1, but it does not disclose the leucovorin + 2,400 mg/m² 5‑FU combination → supports §103, not §102 anticipation.
• Chen L, et al., "Phase 1 study of liposome encapsulated irinotecan (PEP02) in advanced solid tumor patients," ASCO, May 30–Jun. 3, 2008.
• Chibaudel B, et al., "PEPCOL: … PEP02 (MM‑398) or irinotecan in combination with leucovorin and 5‑fluorouracil … metastatic colorectal cancer," ASCO 2015 (post‑priority; relevant to combination concept only).
• PharmaEngine "PEP02" webpage, Aug. 4, 2011; ClinicalTrials.gov NCT00813163 ("A Phase II Study of PEP02 as a Second Line Therapy for Patients with Metastatic Pancreatic Cancer"), Jan. 12, 2015 update.
• Background NPL also cited: Baker J, et al., "Irinophore C, a novel nanoformulation of irinotecan … enhances the distribution of 5‑fluorouracil and doxorubicin," Clin Cancer Res. 14(22):7260‑71 (2008) — relevant to the "increased tumor vascularity"/co‑administration concept.

4. Bottom line — most relevant art and anticipation assessment

1. Most relevant citations

• Liposomal‑irinotecan element: the Hong "Liposomes useful for drug delivery" family (US 8,147,867; 8,329,213; 8,703,181; 8,992,970; US 2015/0182460) — this is the MM‑398 composition itself.
• Liposome‑entrapped topoisomerase inhibitor element: Slater (US 6,465,008; US 6,355,268; US 2002/0146450) and Madden (US 7,060,828).
• Camptothecin + 5‑FU combination element: Achterrath (US 6,403,569 and US 6,794,370).
• Indication element (gemcitabine‑refractory metastatic pancreatic cancer): Ko et al., ASCO 2011 (NPL).

1. Anticipation (§102) — On the face of these citations, none appears to anticipate any of claims 1–16. To anticipate, a single reference must disclose all elements, arranged as in the claim: liposomal (MM‑398) irinotecan at 80 mg/m², plus leucovorin at 200 mg/m² (l) / 400 mg/m² (l+d), plus 5‑FU at 2,400 mg/m², administered IV to a patient with metastatic adenocarcinoma of the pancreas previously treated with gemcitabine. The cited references split these elements (formulation art on one hand; camptothecin/5‑FU combination art on the other), and none combines the liposomal form with the specific LV/5‑FU doses and the post‑gemcitabine pancreatic indication. The realistic grounds are therefore §103 obviousness combinations, not §102 anticipation.

2. Caveat on the "potential §102" framing — Precision here would require (a) the actual examiner citations and their §102(a)/(b)/(e) categories, (b) the effective filing dates of the Hong family members (to confirm §102(e) status), and (c) the complete foreign‑patent‑document and NPL annexes of the '497, which I could not fully retrieve. My characterization above is a screening‑level, source‑grounded assessment, not a legal conclusion of validity or anticipation.

Sources consulted: Google Patents US9339497B2 (authoritative full text supplied); FreePatentsOnline record for 9339497 (citation list); Justia records for US 2015/0328156, US 10,980,795, US 11,344,552 (family claims/NPL); DrugPatentWatch and PharmaCompass entries for patent 9,339,497 (ONIVYDE/NDA 207793, Orange Book use code U‑1848, expiry 2033‑06‑12).

I'll ground this analysis in the actual prior-art record for US 9,339,497. Let me pull the cited references and key secondary references.

Let me pull the specific prior-art references cited against this family and the litigation/PGR record.

A. What the prior-art record actually contains (and what it doesn't)

Before the analysis, an important sourcing note. The "Prior Art" field of the US 9,339,497 Google Patents page as fetched supplies only metadata — "Prior art keywords: leucovorin, patient, administered, dose, administration" and "Prior art date 2012‑06‑13" — plus the filing/priority chain. It does not render the citation list. I therefore reconstructed the art from:

• the front-page US patent references and non-patent citations on the family (FreePatentsOnline citation list for 9,339,497; the non-patent citations table on TWI630924B),
• the related-family PGR/IPR record (petition 1557313 at ptacts.uspto.gov), and
• the FDA/EMA regulatory record for the NAPOLI‑1 (MM‑398‑07‑03‑01) and PEP0203 studies.

I flag explicitly below where I could not verify a publication date in this session. Two structural caveats:

1. The "Full patent text" supplied stops at section VIII (Outcomes). It does not include the claims. The claim text used below is from the secondary listing at drugpatentwatch (US 9,339,497), not from an official claims page. This matters because the granted claim 1 appears materially narrower than the published embodiments — the granted claim is directed to gemcitabine‑pretreated metastatic pancreatic adenocarcinoma at 80 mg/m² q2w with LV + 5‑FU and no other antineoplastic agent, and (per that listing) contains no UGT1A1*28 limitation, even though the specification devotes a long section to UGT1A1. If that listing is accurate, several of the prosecution‑era arguments about genotype‑guided dosing do not even reach granted claim 1.
2. Critical date. The earliest provisional is 61/659,211 (2012‑06‑13); a second provisional 61/784,382 is 2013‑03‑14; the PCT (PCT/US2013/045495) was filed 2013‑06‑12. Both provisionals pre‑date the AIA's 16 March 2013 transition, so pre‑AIA §§ 102/103 (KSR, Graham factors) is the likely governing standard. Every reference relied on below pre‑dates both candidate critical dates (2012‑06‑13 and 2013‑06‑12), so the analysis is robust to that dispute.

---

B. Person of ordinary skill

A POSA here is plausibly a team: (i) a medical oncologist with 2–5 years' experience in GI/pancreatic malignancies and irinotecan handling, and (ii) a formulation/pharmacokinetics scientist familiar with PEGylated liposomal drug delivery and the Camptosar® label. Key to the analysis is what that team knew as of mid‑2012: irinotecan's role in pancreatic cancer (Conroy 2011), the liposomal‑irinotecan (MM‑398) composition itself (US 8,147,867), the q2w 5‑FU/LV "de Gramont/FOLFIRI" backbone, and the FDA‑mandated UGT1A1*28 dose adjustment on the irinotecan label.

---

C. The claims to be analyzed

Granted claim 1 (as listed) requires, in a gemcitabine‑pretreated metastatic pancreatic adenocarcinoma patient: IV 80 mg/m² MM‑398 q2w + 200 mg/m² (l)‑LV or 400 mg/m² (l+d)‑LV + 2,400 mg/m² 5‑FU, with no other antineoplastic agent. Dependent claims add: 400 mg/m² racemic LV (2); administration "over 48 hours" (3); LV before 5‑FU (4); MM‑398 before LV (5); dexamethasone + 5‑HT3 pre‑medication (6); progression on gemcitabine‑based therapy (7); MM‑398 over 90 min (8); LV over 30 min and 5‑FU over 46 h (9); the full sequence MM‑398 90 min → LV 30 min → 5‑FU 46 h (10); day 1 of a 2‑week multi‑cycle schedule with racemic LV (11); and a parallel independent claim 12.

Note how little is left once the Conroy regimen is laid beside this claim: Conroy's FOLFIRINOX is q2w, LV 400 mg/m², 5‑FU 400 mg/m² bolus + 2,400 mg/m² as a 46‑hour infusion, and irinotecan 180 mg/m². The delta between the prior art backbone and claim 1 is therefore only: (a) swap free irinotecan → liposomal irinotecan MM‑398, (b) select the 80 mg/m² dose, and (c) omit oxaliplatin.

---

D. Ground 1 (primary): Hong '867 + Conroy + Cantore (± the Camptosar label)

References.

• US 8,147,867 B2 (Hong, Drummond, Kirpotin; filed 2005‑05‑02; granted 2012‑04‑03) — "Liposomes useful for drug delivery." Expressly claims a liposomal irinotecan/sucrose octasulfate composition with ≥24 h half‑release, and recites that it is "at least 4‑fold" (claim 3) and "at least 10‑fold" (claim 5) more active than free irinotecan against a human colon carcinoma xenograft at the same dose and schedule. The '497 specification itself identifies this patent as the MM‑398 formulation ("see U.S. Pat. No. 8,147,867").
• Conroy et al., NEJM 2011;364:1817–25 (PRODIGE 4/ACCORD 11) — established FOLFIRINOX as a first‑line standard in metastatic pancreatic adenocarcinoma; the FDA's own NAPOLI‑1 review describes it as the reference first‑line regimen and quotes its exact dose/schedule (oxaliplatin 85 mg/m², irinotecan 180 mg/m², LV 400 mg/m², 5‑FU 2,400 mg/m² over 46 h, q2w), available via the FDA cross‑discipline review.
• Cantore et al. — FOLFIRI in gemcitabine‑refractory advanced pancreatic cancer. I could not verify this reference's exact publication date in this session; the family's PGR record (petition 1557313) lists "Cantore" among the art asserted for irinotecan‑in‑pancreatic‑cancer and second‑line/gemcitabine‑failure teachings. If its date is post‑2012, substitute Brixi‑Benmansour et al., Dig Liver Dis 43(11):912–16 (2011) (first‑line FOLFIRI in metastatic pancreatic carcinoma), which is listed among the non‑patent citations on the family (TWI630924B).
• Camptosar® (irinotecan HCl) approved labeling, revised 2005 — genotype information and the recommendation of a reduced starting dose in UGT1A1*28 homozygotes.

Element mapping.

Motivation to combine. Conroy makes irinotecan a validated active agent in exactly the claimed disease, and attributes a large share of FOLFIRINOX's toxicity to the irinotecan component (the FDA/EMA documents, and the later PGR record, both note irinotecan's contribution to FOLFIRINOX bone‑marrow and GI toxicity). Hong '867 then supplies a formulation of the same drug with (i) 4–10× greater preclinical activity than free irinotecan at the same dose/schedule, (ii) prolonged tumor exposure and higher intratumoral SN‑38, and (iii) a PK profile permitting lower administered doses. A POSA seeking to preserve irinotecan's pancreatic‑cancer benefit while reducing its dose‑limiting toxicity had a clear, finite, and identified path: substitute the long‑circulating liposomal irinotecan for free irinotecan in the established q2w 5‑FU/LV backbone, at the dose that had already been identified as the MTD of MM‑398 in combination with 5‑FU/LV.

Reasonable expectation of success. High. The mechanism (topoisomerase I inhibition + thymidylate synthase inhibition with folate potentiation) was known and complementary; the backbone doses were already validated; the substitution was of a formulation of the very same active moiety; and MM‑398 monotherapy responses had been observed in a Phase I solid‑tumor study including pancreatic patients (PEP0203/PEP02 Phase I, Peter Mac/ASCO 2010‑era reports cited in the family record). Under KSR, this is the paradigm case: "a finite number of identified, predictable solutions" and "a reasonable expectation of success," plus routine optimization of dose/schedule (In re Aller; In re Boesch). The choice of 80 mg/m² is not inventive where the MTD in combination with 5‑FU/LV was already 80 mg/m².

---

E. Ground 2 (alternative): Hong '867 + MM‑398/5‑FU‑LV Phase I (PEP0203) + Conroy (or de Gramont/FOLFIRI)

If one credits the MM‑398 clinical data as pre‑critical‑date art (the PEP0203 dose‑escalation of MM‑398 with 5‑FU/LV identified 80 mg/m² as the recommended dose/MTD; the EMA assessment report confirms MTD = 80 mg/m²), then this ground is even tighter:

• PEP0203 already teaches MM‑398 + 5‑FU + LV in a cycle, with an 80 mg/m² recommended dose;
• Conroy already teaches the q2w, 2,400 mg/m²/46 h 5‑FU + 400 mg/m² LV schedule for metastatic pancreatic cancer;
• Hong '867 already teaches the MM‑398 composition.

Combining them yields every element of claim 1 (and claim 2's racemic LV, claims 8–10's infusion durations). The only remaining choice — running the combination on the 2‑week FOLFIRI/FOLFIRINOX cadence rather than a 3‑week cadence — is a schedule optimization supported by the twice‑weekly 5‑FU/LV backbone's well‑known ability to be paired with biweekly irinotecan.

Caveat: I could not confirm in this session whether the PEP0203 combination data were publicly available before 2012‑06‑13. The '497 specification presents PEP0203 Tables 1–2 as its own Examples, and the EMA lists PEP0203 among studies to which Merrimack had direct database access, which suggests it may not be prior art. Ground 1 does not depend on PEP0203, which is why Ground 1 is the better vehicle.

---

F. Ground 3: dependent claims

• Claims 2, 9 (LV 400 mg/m² racemic; 5‑FU over 46 h): literal disclosures of Conroy.
• Claims 4, 5, 10 (order of administration): sequence is a classic routine‑optimization variable. In the sibling PGR record the Board reasoned that "the particular timing of administration of the drugs relative to one another would have been a subject of routine optimization within the POSA's skill," citing Masi (irinotecan before oxaliplatin) and Ginocchi (modified FOLFOXIRI in pancreatic cancer). For MM‑398 specifically, the same record notes that when toxicity concerns arise the option is to slow the infusion rate. A negative or ordering limitation that produces no new technical effect is not patentably distinct.
• Claim 6 (dexamethasone + 5‑HT3 pre‑medication): the Camptosar label and standard institutional irinotecan practice recite exactly this pre‑medication. The '497 specification itself concedes it is "as per standard institutional practices for irinotecan administration" — an admission of conventionality.
• Claims 7 (progression on gemcitabine), 8 (90‑min MM‑398 infusion): gemcitabine‑progression is the claimed NAPOLI‑1 population and is taught by second‑line‑after‑gemcitabine art (CONKO‑003/Pelzer as described in the FDA review; FOLFIRI in gemcitabine‑refractory disease). A 90‑minute slow infusion for a PEGylated liposome is standard liposome‑infusion practice (infusion‑reaction mitigation) and is what the MM‑398 Phase I protocol used.
• Any UGT1A1‑dependent claims (if present in claims 12+): squarely taught by the 2005 Camptosar label revision recommending a reduced starting dose in *28/*28 patients, by Innocenti et al., JCO 2004 (grade 4 neutropenia in 3/6 *28/*28 patients at 350 mg/m²), and by Tan et al., JCO 2008 (prospective genotype‑guided dose reduction abolished grade 4–5 neutropenia). A reduced starting dose with escalation to the standard dose upon tolerability is the express teaching of the label and of the guidance literature.

---

G. Anticipated Patent Owner (POP) arguments, and their weaknesses

1. "The combination is synergistic / unexpected." The specification asserts "therapeutic synergy," but the regulatory record undercuts a strong synergy story: in NAPOLI‑1, MM‑398 monotherapy vs 5‑FU/LV gave HR ≈ 0.99 for OS, and the combination's median OS gain over 5‑FU/LV was 1.9 months (6.1 vs 4.2), with the EMA noting the benefit was not demonstrated in prior‑irinotecan patients. A modest additive benefit over a well‑matched control is closer to expected additivity than to superadditivity, and synergy cannot be established merely by assertion — it requires a statistical interaction test or a comparison against each constituent at its own optimal dose.
2. "Liposomal irinotecan needs a different dose; 180 mg/m² cannot be transposed." Correct, and the art already answers it: Hong '867 teaches the altered PK and the 80 mg/m² MTD in combination with 5‑FU/LV was already reported. Selecting the disclosed MTD is not invention.
3. "The prior art points to FOLFIRINOX (four drugs); claim 1 excludes oxaliplatin." This is a narrowing relative to the closest art, not a patentable advance. A negative limitation is obvious when the excluded element is optional in the prior art (MPEP 2144.06; In re Johnson). FOLFIRI‑type regimens without oxaliplatin are expressly known in pancreatic cancer (Brixi‑Benmansour 2011; Cantore), so the "no other antineoplastic agent" limitation is met by prior art regimens in which oxaliplatin is simply absent.
4. "Method‑of‑treatment claims are entitled to weight as new uses." The claims recite no new composition and no new mechanism; the asserted novelty is dose/schedule/patient selection on known agents — the weakest class of claims under § 103 (In re Kao; Pfizer v. Apotex).

---

H. Bottom line and open questions

Assessment. On the record available, each independent claim of US 9,339,497 (as listed) is vulnerable to a § 103 challenge, most plausibly on the primary combination US 8,147,867 (Hong) + Conroy 2011 FOLFIRINOX + a FOLFIRI‑in‑pancreatic‑cancer reference (Cantore/Brixi‑Benmansour), optionally with the Camptosar label and the PEP0203 80 mg/m² MTD. The dependent claims are weaker still, since almost all of them (LV 400 mg/m², 5‑FU 46 h, q2w, racemic LV, pre‑medication, infusion sequencing) are verbatim features of the Conroy regimen or of standard irinotecan practice, and the order‑of‑administration claims were held to be routine optimization in the sibling PGR proceeding.

Open items I could not close in this session and that would need verification before relying on this analysis:

• The official granted claim text for 9,339,497 (the supplied full text omits the claims; the listing I used is secondary and shows no UGT1A1 limitation, which is a meaningful discrepancy versus the published application).
• Exact bibliographic dates for Cantore, Masi, Ginocchi, Saif, Ko, Mahaseth and Carnevale — these appear in the family's PGR grounds, but I could not verify their pre‑2012 publication status here.
• Whether the PEP0203 combination results were public before 2012‑06‑13 (if they were, Ground 2 becomes the strongest ground; if not, Ground 1 stands).
• Whether any granted claim requires the March 14, 2013 provisional for support, and how the AIA/pre‑AIA transition was resolved for this chain (I treated both dates as working critical dates, which the reference set satisfies either way).

A timing observation worth noting, though it is not prior art (it post‑dates the earliest priority date and is a confidential protocol): the FDA review states that NAPOLI‑1 Protocol Amendment 1, dated 14 June 2012 — one day after the 2012‑06‑13 priority date — is what added the claimed third arm, i.e., MM‑398 80 mg/m² (60 mg/m² start for UGT1A1*28 homozygotes) q2w with 5‑FU 2,400 mg/m² over 46 h and LV 200 mg/m² every 2 weeks. That the claimed regimen was written into the trial protocol essentially contemporaneously with the provisional filing is a fact pattern that tends to reinforce the "routine regimen design" narrative rather than rebut it.

Lastly, note the litigation posture on the family page — US case filed in New Jersey District Court (3:24‑cv‑04991), family has litigation, current assignee Ipsen Biopharm Ltd. Any § 103 opinion should be re‑run against the invalidity contentions actually served in that case, which will identify the precise combinations being asserted.